TCF7 and neoplasm: Furthermore, we checked the composition of intratumoral CD4+ T cells in our scRNA profile and also confirmed a higher proportion of C2-CD4-IL7R and C4-CD4-TCF7 clusters in neoadjuvant chemoimmunotherapy treated tumor lesions (C2-CD4-IL7R: 5.60% versus 10.35% versus 8.61%; C4-CD4-TCF7: 1.63% versus 3.70% versus 4.63%; Fig. 3C), indicating that the B-cell enrichment accompanied with an elevated level of CD4+ T cells in neoadjuvant tumor lesions.